How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

How and Why to Invest in ETFs: Demystifying the Vehicle Taking Markets by Storm Silver pulls back from $32.55 resistance, with key support at $31.81. Traders await NFP data for the next market move.

March 1, 2026 • This week on In Black America, producer and host John L. Hanson, Jr. presents a conversation with Michelle Adams, law professor at the University of Michigan Law School, and author of ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.